metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Effects of androgen deprivation therapy on elderly men with high-risk prostate c...
Journal Information
Vol. 48. Issue 4.
Pages 304-310 (May 2024)
Share
Share
Download PDF
More article options
Visits
3
Vol. 48. Issue 4.
Pages 304-310 (May 2024)
Original article
Effects of androgen deprivation therapy on elderly men with high-risk prostate cancer: PROSARC observational study
Efectos de la privación androgénica en cáncer de próstata de alto riesgo en ancianos: estudio observacional PROSARC
Visits
3
Ó. Legido-Gómeza,
Corresponding author
oscarlg9@hotmail.es

Corresponding author.
, S. Rico-Marcoa, M.V. Lorenzo-Sáncheza, S. Navarro-Jiméneza, M.A. Tárraga-Honrubiaa, J. Martínez-Ruiza, J.M. Giménez-Bachsa, M.J. Donate-Morenoa, I. Díaz de Mera-Sánchez-Migallóna, M. Segura-Martína, R. Alcantud-Córcolesb, P. Abizanda-Solerb, A.S. Salinas-Sáncheza
a Servicio de Urología, Hospital General Universitario de Albacete, Albacete, Spain
b Servicio de Geriatría, Hospital Universitario Nuestra Señora del Perpetuo Socorro, Albacete, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Sociodemographic and oncologic characteristics of subjects and 6-month evaluation after ADT initiation.
Abstract
Introduction

Prostatic carcinoma (PC) is a frequent neoplasm in elderly patients. Although androgen deprivation is associated with survival benefits, it is also related to adverse effects such as osteoporosis, frailty, or sarcopenia, which can negatively affect the patient’s quality of life. This study aims to quantify and evaluate the prevalence of osteoporosis, frailty, or sarcopenia in elderly PC patients before and after androgen deprivation. We present data from an interim analysis.

Materials and methods

PROSARC is a national (Spain) prospective observational study (May-2022–May-2025) still in progress in 2 hospitals. It includes patients with high-risk PC, aged ≥70 years, non-candidates for local treatment and scheduled to start androgen deprivation therapy. The following variables are analyzed: comorbidity, frailty (Fried frailty phenotype criteria), osteoporosis, sarcopenia (EWGSOP2), fat mass and muscle mass, before treatment and after 6 months of follow-up.

Results

A 6-month follow-up was completed by 12/25 included patients (mean age, 84 years), with a high baseline prevalence of pre-frailty/frailty (67.7%), sarcopenia (66.7%) and osteoporosis (25%). Treatment did not significantly alter these variables or comorbidity. We observed changes in body mass index (p=0.666), decreased mean value of appendicular muscle mass (p=0.01) and increased percentage of fat mass (p=0.012).

Conclusion

In patients with high-risk PC, advanced age and a considerable prevalence of osteoporosis, frailty and sarcopenia, androgen deprivation (ADT; 6 months) produces decreased muscle mass without impact on the incidence of the known adverse effects of androgen deprivation.

Keywords:
Prostate cancer
Androgen deprivation
Frailty
Muscle mass
Resumen
Introducción

El carcinoma prostático (CP) es una neoplasia frecuente en pacientes de edad avanzada. La privación androgénica, con beneficio en supervivencia, se relaciona con efectos adversos tales como osteoporosis, fragilidad o sarcopenia, que pueden impactar negativamente en la calidad de vida del paciente. Este estudio pretende cuantificar y evaluar el estado de osteoporosis, fragilidad o sarcopenia en pacientes con CP de edad avanzada antes y después de la privación androgénica. Presentamos datos de un análisis intermedio.

Materiales y métodos

Estudio nacional (España) observacional prospectivo, PROSARC, aún en marcha (mayo del 2022-mayo del 2025) en 2 hospitales. Incluye a pacientes con CP de alto riesgo, ≥ 70 años, no candidatos a tratamiento local e inicio programado de privación androgénica. Se analizan las siguientes variables: comorbilidad, fragilidad (criterios de Fried), osteoporosis, sarcopenia (EWGSOP2), masa grasa y masa muscular, antes del tratamiento y tras 6 meses de seguimiento.

Resultados

Completaron un seguimiento de 6 meses 12/25 pacientes incluidos (edad media, 84 años), con una elevada prevalencia basal de prefragilidad/fragilidad (67,7%), sarcopenia (66,7%) y osteoporosis (25%). El tratamiento no varió significativamente estas variables ni la comorbilidad. Se observaron cambios en el índice de masa corporal (p=0,666), reducción del valor medio de la masa muscular apendicular (p=0,01) e incremento del porcentaje de masa grasa (p=0,012).

Conclusión

La privación androgénica (6 meses) en pacientes con CP de alto riesgo, edad avanzada y una prevalencia considerable de osteoporosis, fragilidad y sarcopenia, produce disminución de masa muscular sin que ello repercuta en la incidencia de los efectos adversos de la privación androgénica estudiados.

Palabras clave:
Cáncer de próstata
Privación androgénica
Fragilidad
Masa muscular

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.acuroe.2021.09.001
No mostrar más